Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

Figure 2

mTOR signaling activity is increased in Hodgkin-lymphoma cell lines. a. The amount of phosphorylated 4EBP1 protein is elevated in KMH2 Hodgkin-lymphoma cell line compared to normal B-cells, T-cells and buffy coat samples. (ELISA; p<0.05) b. Confirmation of mTOR activity in HL cell lines (KMH2, L428, UH-01, DEV, L1236, HDML2) by pS6 (A-C) and pmTOR (D-F); ICC (400X). c. mTOR kinase and phosphorylated proteins related to its activity (pmTOR, pp70S6K and pS6) in Hodgkin-lymphoma cells detected by Western-blotting. mTOR activity is rapamycin-sensitive in HL cell lines (Co: control; R: rapamycin-treated cells). Representative results showed in KMH2 HL cell line.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us